# Pharmerging Market

> Pharmerging Market Research Report By Product Type (Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology, Generics), By Application (Therapeutic, Diagnostic, Preventive, Research and Development), By Disease Area (Cancer, Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, Neurological Disorders), By Business Model (Branded Generics, Biosimilars, Innovative Therapeutics, Diagnostics and Monitoring Devices, Contract Research and Manufacturing Organizations), By Distribution Channel (Hospitals and Clinics, Retail Pharmacies, Online Marketplaces, Wholesale Distributors, Direct-to-Consumer) and By Regional - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.96%
- **2025:** USD 2,028.4 Billion
- **2035:** USD 4,775.4 Billion
- **Key Players:** Sanofi, Pfizer, Novartis (incl. Sandoz legacy), AstraZeneca, GSK, Sun Pharmaceutical Industries, Abbott, Cipla

**Report ID:** MRFR/HC/27495-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** September 07, 2026

**URL:** https://www.marketresearchfuture.com/reports/pharmerging-market-29204

---

## Market Summary

## Pharmerging Market Summary

The Pharmerging Market reached USD 2,028.4 billion in 2025 and is projected to grow to USD 4,775.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 8.96% between 2026 and 2035. Market value is expected to reach USD 2,217.0 billion in 2026 as the first year of the forecast period. This growth is being driven primarily by expanding public insurance coverage in India and reimbursement drug list expansion in China, alongside a broader supply-chain shift toward serialized, traceable [pharmaceutical](https://www.marketresearchfuture.com/reports/pharmaceutical-market-67551) distribution.

India's Ayushman Bharat PM-JAY scheme now underwrites hospitalization for roughly 550 million citizens, representing one of the largest public [health insurance](https://www.marketresearchfuture.com/reports/health-insurance-market-8227) expansions in the world. China's National Reimbursement Drug List expansions added more than 90 therapies in the 2024 negotiation round. Neither development is a marketing initiative; both are converting latent clinical need into billed, reimbursed prescriptions at significant scale.

Manufacturing and distribution infrastructure is also being rebuilt beneath this demand growth. Paper-based wholesaler ledgers and unserialized secondary packaging are giving way to GS1-compliant track-and-trace systems, cloud-based order management, and temperature-logged cold chain logistics. Brazil's ANVISA serialization mandate and India's Production Linked Incentive scheme, which has committed INR 15,000 crore across pharmaceutical tranches, are forcing this infrastructure upgrade rather than merely encouraging it.

By region, Asia-Pacific holds the largest share of the Pharmerging Market, at 36.8%, on the strength of Chinese and Indian volume, and it is also the fastest-growing region, with a projected CAGR of 11.06%. Europe's pharmerging bloc, comprising Russia, Türkiye, and Poland, holds the second-largest share, at 21.5%, supported by domestic substitution policy. Through 2035, the decisive factor for this market is expected to be not the level of demand itself, but whether supply chains and pricing regimes can absorb it.

## Key Report Takeaways

### • By Product Type

- Branded generics command 43.3% of the Pharmerging Market, the widest single product block
- Biosimilars post the fastest product-type expansion at an 11.61% CAGR through 2035
- Vaccines contribute roughly USD 184.6 billion in 2025 revenue

### • By Therapeutic Area

- Anti-infectives account for 19.9% of therapeutic demand
- Oncology advances at a 10.85% CAGR as tender-based access widens

### • By Region

- Asia-Pacific holds 36.8% of the Pharmerging Market
- North America's pharmerging component reaches USD 308.3 billion in 2025, led by Mexico
- South America grows at a 9.62% CAGR on Brazilian public procurement

## Market Size and Forecast (2021–2035)

Sizing blends audited revenue disclosures from 40 listed manufacturers, IQVIA MIDAS-equivalent prescription audits, national reimbursement expenditure filings, and customs-level import data across 21 pharmerging economies. Historical values are reconciled to constant 2025 US dollars; forecast values apply therapy-class demand modelling layered onto reimbursement enrolment curves.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Universal health coverage expansion | ~2.1 | India, China, Indonesia, Brazil | Long-term (≥4 yr) | [1][7] |
| Chronic disease burden from urbanisation | ~1.8 | Asia-Pacific, MEA | Long-term (≥4 yr) | [9] |
| Domestic manufacturing incentives | ~1.4 | India, China, Saudi Arabia | Medium-term (2–4 yr) | [3][10] |
| Retail pharmacy chain consolidation | ~1.2 | Brazil, Mexico, Türkiye | Medium-term (2–4 yr) | [11] |
| Biosimilar approval acceleration | ~1.1 | China, India, Russia | Medium-term (2–4 yr) | [6] |
| Digital prescription and telehealth uptake | ~0.9 | Southeast Asia, Africa | Short-term (≤2 yr) | [12] |
| Multinational R&D relocation | ~0.7 | China, India | Long-term (≥4 yr) | [13] |

### Universal Health Coverage Becomes a Purchase Order

Coverage schemes take expenditure out of household pockets and into state balance sheets — and that changes therapy mix overnight. PM-JAY has sanctioned more than 80 million hospitalizations since its commencement, with a total outlay of more than INR 1.2 lakh crore [[1]](https://pmjay.gov.in). Injectables and cancer regimens often bypassed by out-of-pocket customers are given to hospitalized patients.

### Chronic Disease Follows the Cities

Urban migration consistently increases the incidence of diabetes and cardiovascular disease. In China alone, the International Diabetes Federation estimates that 148 million persons are living with diabetes and that treatment coverage remains less than 40% [[9]](https://diabetesatlas.org). Each percentage point of coverage gain is not a one-time demand event, but a sustained, multi-year driver of prescription volume.

### Incentives Are Rebuilding the Supply Base

India’s Production Linked Incentive plan has disbursed against 55 approved bulk-drug and formulation projects, aimed at import substitution on 41 critical starting materials [[3]](https://pharmaceuticals.gov.in). Saudi Arabia’s localization initiative, meanwhile, demands 25% domestic sourcing by 2030 in government tenders [[10]](https://sfda.gov.sa), thus guaranteeing offtake for new factories.

### Pharmacy Retail Turns Professional

Chain consolidation replaces fragmented independents with data-rich formats. Brazil's top three drugstore groups now operate more than 6,500 outlets combined [[11]](https://abrafarma.com.br), giving manufacturers negotiated shelf placement, loyalty-linked adherence programmes, and point-of-sale visibility that simply did not exist a decade ago.

## Restraints

## Restraints Impact Analysis

Restraint weightings reflect directional drag on the growth trajectory, scored on enforcement breadth and margin sensitivity. They are not subtractive inputs to the CAGR calculation.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Statutory price control and tendering | ~-1.6 | China, India, Türkiye | Long-term (≥4 yr) | [8][14] |
| Cold-chain and last-mile infrastructure gaps | ~-1.1 | Sub-Saharan Africa, ASEAN | Medium-term (2–4 yr) | [15] |
| Substandard and falsified medicines | ~-0.8 | Africa, South Asia | Long-term (≥4 yr) | [16] |
| Currency volatility on imported inputs | ~-0.7 | Argentina, Türkiye, Egypt | Short-term (≤2 yr) | [17] |
| Regulatory divergence across jurisdictions | ~-0.5 | All pharmerging geographies | Medium-term (2–4 yr) | [18] |

### Volume-Based Procurement Compresses Value

China has undertaken eleven nationwide centralized volume-based tenders, with average winning bids achieving price reductions of over 50% compared to pre-tendering pricing levels [[8]](https://oecd.org). Turn up the volume; revenue per unit plummets. Manufacturers that can’t get to tender-grade cost structures drop out of the molecule altogether, and that value degradation gets absorbed by the Pharmerging Market in aggregate revenue terms.

### The Cold Chain Still Breaks

The WHO estimates that globally, up to half of vaccination doses are wasted each year, with temperature excursion a main reason in low-infrastructure settings [[15]](https://who.int). The fastest-expanding product tier is biologics and biosimilars. These are exactly the items least tolerant of that failure pattern, capping realistic penetration beyond tier one cities.

### Falsified Product Erodes Trust and Price

WHO review data indicate roughly one in ten medical products circulating in low- and middle-income countries is substandard or falsified [[16]](https://who.int). The commercial cost is twofold: direct volume displacement, and a durable consumer preference for imported brands over locally manufactured equivalents.

## Opportunities

## Pharmerging Market Opportunities

### Biosimilar Substitution at Tender Scale

More than USD 60 billion of biologic originator revenue faces loss of exclusivity globally through 2030 [[6]](https://iqvia.com/institute). Pharmerging payers, unburdened by legacy prescriber loyalty, can switch tender-wide in a single cycle — a speed advantage no mature market offers.

### E-Pharmacy in Underserved Geographies

Digital channels reach patients that physical retail never will. Southeast Asia added 100 million new internet users between 2019 and 2024 [[12]](https://itu.int), and prescription fulfilment platforms are converting that reach into adherence programmes with measurable refill economics.

### Real-World Evidence as a Revenue Line

Nationwide reimbursement databases in China, Brazil, and India generate longitudinal outcome data at population scale. Licensing anonymised evidence packages to global regulators and payers creates a second monetisation path independent of unit sales.

### Africa's Local Manufacturing Build-Out

The African Medicines Agency and the PAVM framework target 60% of the continent's vaccine requirement produced locally by 2040 [[19]](https://gavi.org). Technology-transfer partnerships entered now secure preferential procurement status later.

### Specialty Distribution for Oncology

Oncology's 10.85% CAGR outpaces the distribution infrastructure available to serve it. Dedicated specialty distributors handling cold storage, patient support, and reimbursement navigation can capture margin that traditional wholesalers cannot defend.

## Future Outlook

## Pharmerging Market Future Outlook

### AI Moves Into Demand Planning

Forecasting error, not manufacturing capacity, drives most stockouts in emerging distribution networks. Machine-learning demand models trained on reimbursement claims are cutting district-level stockout rates materially in pilot deployments, and the World Bank has flagged supply-chain analytics as a priority investment area for health system lending [[24]](https://worldbank.org).

### Platform Economics Reach the Pharmacy Counter

Aggregators are collapsing the wholesaler tier. Independent pharmacies gain credit lines, inventory financing, and private-label access in exchange for order-flow visibility — a structural shift that redistributes margin toward whoever owns the ordering interface rather than the warehouse.

### Biologics Capacity Localises

Single-use bioreactor systems have cut greenfield biologics plant costs and build timelines sharply, putting regional manufacturing within reach of mid-tier economies. The pharmerging healthcare growth story through 2035 depends heavily on whether that capacity certifies to stringent-regulator standards.

### ESG Disclosure Becomes a Tender Criterion

Antimicrobial manufacturing discharge and Scope 3 emissions are entering procurement scorecards. The AMR Industry Alliance now publishes discharge targets for over 100 antibiotic APIs [[25]](https://amrindustryalliance.org), and tender authorities in South Africa and Brazil have begun referencing comparable standards in qualification documents.

## Segment Insights

## Pharmerging Market Segmentation

### By Product Type

Branded generics dominate the Pharmerging Market because physician and patient trust attaches to the brand, not the molecule.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Branded Generics | 43.3% share | Prescriber loyalty and detailing reach |
| Patented Drugs | USD 426.0 Billion | Private insurance and self-pay specialty demand |
| OTC Pharmaceuticals | 16.4% share | Retail self-medication culture |
| Biosimilars | 11.61% CAGR | Tender-driven originator substitution |
| Vaccines | USD 184.6 Billion | National immunisation programme funding |

Branded generics survive price pressure that unbranded equivalents cannot, because the premium buys pharmacist recommendation and perceived quality assurance in markets where falsification is a live concern. Biosimilars represent the opposite logic — pure economics at tender scale, with switching decisions made by payers rather than prescribers.

### By Therapeutic Area

Therapeutic mix inside the Pharmerging Market is shifting from acute to chronic faster than most forecasts assumed a decade ago.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Anti-Infectives | 19.9% share | Communicable disease burden and empiric prescribing |
| Cardiovascular | USD 369.2 Billion | Hypertension screening programme expansion |
| Oncology | 10.85% CAGR | Reimbursement listing of targeted therapies |
| Diabetes | 15.1% share | Urban prevalence and treatment coverage gains |
| Respiratory | USD 249.5 Billion | Air quality and COPD diagnosis rates |
| Others | 17.1% share | Neurology, dermatology, women's health |

Anti-infectives still lead on volume, but the revenue centre of gravity is moving. Oncology's ascent reflects a specific policy mechanic: once a targeted therapy enters a national reimbursement list, uptake is near-vertical because diagnosed patient backlogs release all at once.

### By Distribution Channel

Channel structure across the Pharmerging Market remains retail-weighted, though the digital tier is compounding fastest.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Retail Pharmacies | 55.7% share | Out-of-pocket purchasing and proximity |
| Hospital Pharmacies | USD 576.1 Billion | Inpatient procurement and injectable dispensing |
| E-Commerce Platforms | 12.16% CAGR | Smartphone penetration and refill convenience |
| Others | 6.3% share | Dispensing physicians and rural depots |

Retail Pharmacies lead the Pharmerging Market by distribution channel with a dominant 55.7% share in 2025, operating as the primary point of care where high out-of-pocket spending, OTC drug demand, and immediate neighborhood proximity drive consumer prescription fills. Meanwhile, E-Commerce Platforms represent the fastest-growing distribution channel, projecting a market-leading CAGR of 12.16%, propelled by surging smartphone penetration, expanding e-pharmacy ecosystems, and the growing convenience of digital prescription refills across rapidly urbanizing emerging economies.

### By Formulation

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Solid Oral | 47.6% share | Cost efficiency and ambient stability |
| Injectables | 11.17% CAGR | Biologics and hospital-administered therapy |
| Liquid Oral | USD 383.4 Billion | Paediatric and geriatric dosing |
| Others | 10.8% share | Topical, inhalation, transdermal |

Solid oral formats persist because they tolerate the ambient-temperature reality of most distribution networks. Injectables grow faster precisely where cold-chain investment has landed, which makes the two segments a useful proxy for infrastructure maturity by country.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | USD 308.3 Billion | Mexican public procurement reform, nearshored API capacity |
| Europe | 21.5% share | Domestic substitution, Türkiye export hub build-out |
| Asia-Pacific | 36.8% share | NRDL expansion, PLI-backed formulation capacity |
| South America | 9.62% CAGR | ANVISA serialisation, chain pharmacy consolidation |
| Middle East & Africa | USD 233.3 Billion | Localisation quotas, continental vaccine manufacturing |
| Total | USD 2,028.4 Billion | — |

Regional performance in the Pharmerging Market tracks reimbursement maturity far more closely than it tracks GDP per capita.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Mexico | 61.4% of region | IMSS-Bienestar consolidated procurement |
| US | USD 82.1 Billion | Generic import dependence on pharmerging suppliers |
| Canada | 7.9% of region | Biosimilar switching policy in provincial plans |

Mexico's decision to centralise federal drug purchasing under IMSS-Bienestar reset supplier economics abruptly, and the 2024–2025 mega-tender cycle covered more than 4,000 product codes [[20]](https://gob.mx). Winners gained multi-year volume certainty; losers lost an entire national channel.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Russia | 28.6% of region | Pharma-2030 localisation strategy |
| Türkiye | USD 71.4 Billion | Export hub for MEA and Central Asia |
| Poland | 11.2% of region | Reimbursement list broadening |
| Germany | 9.87% CAGR | Contract manufacturing linkages |
| UK | USD 34.9 Billion | Generic sourcing from Indian suppliers |
| France | 7.4% of region | Biosimilar tender penetration |
| Italy | USD 26.6 Billion | Regional formulary expansion |
| Spain | 5.1% of region | Hospital pharmacy procurement pooling |
| Nordic Countries | 8.62% CAGR | Specialty distribution partnerships |
| Rest of Europe | 6.8% of the region | Central Asian trade corridors |

Russia's Pharma-2030 strategy targets domestic production of the full strategic medicines list, and state programmes have funded more than 60 finished-dosage facilities since 2020 [[21]](https://minpromtorg.gov.ru). Türkiye plays the opposite role — an export platform whose cost base and customs union access make it the natural staging point for MEA-bound generics.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 44.9% of region | NRDL negotiation and VBP volume awards |
| India | USD 168.7 Billion | PM-JAY coverage and PLI capacity |
| Japan | 6.3% of region | Generic substitution targets |
| South Korea | 12.14% CAGR | Biosimilar manufacturing exports |
| ASEAN | 13.7% of the region | Universal coverage rollouts in Indonesia and Vietnam |
| Rest of Asia-Pacific | USD 51.2 Billion | Bangladesh and Pakistan generic capacity |

China anchors the region through sheer reimbursement scale, but Indonesia deserves closer attention: JKN now enrols over 270 million people, making it the largest single-payer system in the world by membership [[7]](https://worldbank.org). That scale converts modest per-capita spending into formidable aggregate demand.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 63.8% of region | SUS procurement and Farmácia Popular |
| Argentina | USD 54.7 Billion | PAMI social security formulary |
| Rest of South America | 9.1% of region | Colombian and Chilean private insurance growth |

Brazil's Farmácia Popular programme subsidises chronic-disease medicines through more than 30,000 accredited private pharmacies [[22]](https://gov.br/anvisa), blending public financing with retail distribution. It is the most commercially interesting hybrid model in the hemisphere and a template several neighbours are studying.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 24.3% of region | Vision 2030 localisation quotas |
| UAE | USD 31.8 Billion | Mandatory health insurance expansion |
| South Africa | 17.6% of region | NHI Act implementation phase |
| Egypt | 10.94% CAGR | Universal Health Insurance Law rollout |
| Rest of MEA | USD 76.5 Billion | Nigerian and Kenyan retail formalisation |

Egypt's Universal Health Insurance Law is being phased governorate by governorate through 2032, ultimately covering the full population [[23]](https://uhia.gov.eg). Manufacturers positioning local fill-finish capacity ahead of each phase gain tender eligibility that late entrants will find difficult to acquire.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is low. Market Research Future estimates an HHI in the 190–230 band, with the top five suppliers holding roughly 15–17% of combined revenue. Domestic champions compete credibly against multinationals on price and distribution depth, and no single firm controls a dominant position in any major pharmerging region.

| Company | Est. Revenue Share Range | Key Offerings for Pharmerging Market | Strategic Positioning |
| --- | --- | --- | --- |
| Sanofi | ~3.4–4.2% | Insulins, vaccines, established brands | Deepest emerging-economy legacy portfolio |
| Pfizer | ~3.0–3.8% | Vaccines, oncology, anti-infectives | Premium innovation tier with tender participation |
| Novartis (incl. Sandoz legacy) | ~2.8–3.6% | Branded generics, cardiovascular, biosimilars | Dual innovator and off-patent play |
| AstraZeneca | ~2.4–3.1% | Oncology, respiratory, diabetes | Strongest China commercial footprint |
| GSK | ~2.1–2.8% | Vaccines, respiratory, HIV | Immunisation programme partner of record |
| Sun Pharmaceutical Industries | ~1.9–2.5% | Branded generics, dermatology, specialty | India volume leader with emerging-economy exports |
| Abbott | ~1.7–2.3% | Nutritionals, established pharmaceuticals | Retail-brand strength in India and South America |
| Cipla | ~1.4–1.9% | Respiratory, anti-infectives, HIV | Access-pricing pioneer across Africa |
| Dr. Reddy's Laboratories | ~1.2–1.7% | Generics, biosimilars, active ingredients | Biosimilar pipeline depth at tender cost |
| Teva | ~1.1–1.6% | Generics, CNS, respiratory | Scale manufacturing with Türkiye and Russia presence |
| Viatris | ~1.0–1.5% | Off-patent brands, ARVs | Broad-basket supplier to public procurement |
| Aspen Pharmacare | ~0.8–1.3% | Anaesthetics, thrombosis, sterile fill-finish | Africa's largest integrated manufacturer |
| Bayer | ~0.8–1.2% | Women's health, cardiovascular, consumer health | Consumer-plus-prescription hybrid model |
| Hikma Pharmaceuticals | ~0.6–1.0% | Injectables, generics | MENA regional leader with US export base |

## Recent News & Developments

## Recent News & Developments

- China NHSA (December 2024): Concluded the annual reimbursement negotiation, adding 91 drugs to the national list and lowering average negotiated prices by more than 60%, reshaping oncology access economics [[2]](https://nhsa.gov.cn).
- India Ministry of Chemicals & Fertilizers (March 2024): Reported PLI-linked pharmaceutical output crossing INR 2.5 lakh crore cumulatively, with 41 key starting materials now produced domestically [[3]](https://pharmaceuticals.gov.in).
- Aspen Pharmacare (June 2024): Secured a multi-year sterile fill-finish supply agreement for the African market, converting idle pandemic-era capacity into commercial biologics volume [[19]](https://gavi.org).

- Saudi FDA (November 2023): Introduced revised localisation scoring in government tenders, granting preference weighting to products with domestic value addition above 25% [[10]](https://sfda.gov.sa).
- Egypt UHIA (August 2025): Extended universal health insurance coverage to three additional governorates, expanding the reimbursed population by an estimated 9 million residents [[23]](https://uhia.gov.eg).
- Gavi (October 2024): Approved a first-tranche African Vaccine Manufacturing Accelerator award structure to underwrite continental production economics through 2035 [[19]](https://gavi.org).

## Frequently Asked Questions

**Q: What contract structures best protect margin when entering tender-driven pharmerging geographies?**
A: Multi-year volume-guaranteed contracts with indexed input-cost clauses outperform single-cycle bids. Suppliers that bundle local fill-finish commitments typically secure preference weighting and renewal priority [10].

**Q: How should investors evaluate acquisition targets in the Pharmerging Market?**
A: Weight distribution reach and field-force density above pipeline value, since branded generics economics rest on prescriber access. Registration portfolios covering three or more regulatory jurisdictions command clear premiums [13].

**Q: What integration challenges arise when a multinational acquires a domestic pharmerging manufacturer?**
A: Data integrity remediation and quality-system harmonisation consume most of the first eighteen months. Retaining the acquired field force intact is the single strongest predictor of revenue continuity [18].

**Q: Which regulatory nuance most often delays product entry in the Pharmerging Market?**
A: Country-specific bioequivalence study requirements rarely accept foreign data outright. Building a reference-product sourcing plan before filing typically removes six to nine months from approval timelines [18].

**Q: How do procurement teams verify supplier quality in fragmented pharmerging supply chains?**
A: Prioritise suppliers with recent stringent-regulator inspection histories and unit-level serialisation capability. On-site audits remain necessary where national inspectorates publish limited enforcement data [16].

**Q: What emerging use cases are opening for specialty pharmacy services in the Pharmerging Market?**
A: Patient support programmes for oncology and biologics adherence are becoming reimbursable in several jurisdictions. Providers combining cold-chain delivery with nurse-led monitoring capture the strongest contracts [11].

**Q: Is local manufacturing always more cost-effective than importing finished product?**
A: No. Below roughly 15 million units annually, imported finished dosage generally beats local fill-finish on landed cost. Localisation pays off through tender preference and tariff avoidance, not unit economics [3].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pharmerging-market-29204*